Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

被引：81

作者：

Peyrin-Biroulet, Laurent ^{[1
,2
]}

Billioud, Vincent ^{[1
,2
]}

D'Haens, Geert ^{[3
]}

Panaccione, Remo ^{[4
]}

Feagan, Brian ^{[5
,6
]}

Panes, Julian ^{[7
]}

Danese, Silvio ^{[8
]}

Schreiber, Stefan ^{[9
]}

Ogata, Haruhiko ^{[10
]}

Hibi, Toshifumi ^{[10
]}

Higgins, Peter D. R. ^{[11
]}

Beaugerie, Laurent ^{[12
,13
]}

Chowers, Yehuda ^{[14
,15
]}

Louis, Edouard ^{[16
,17
]}

Steinwurz, Flavio ^{[18
]}

Reinisch, Walter ^{[19
]}

Rutgeerts, Paul ^{[20
]}

Colombel, Jean-Frederic ^{[21
]}

Travis, Simon ^{[22
]}

Sandborn, William J. ^{[23
]}

机构：

[1] Univ Henri Poincare 1, INSERM, U954, F-54511 Vandoeuvre Les Nancy, France

[2] Univ Henri Poincare 1, Univ Hosp Nancy, Dept Hepatogastroenterol, F-54511 Vandoeuvre Les Nancy, France

[3] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[4] Univ Calgary, Inflammatory Bowel Dis Clin, Calgary, AB, Canada

[5] Robarts Res Inst, London, ON N6A 5C1, Canada

[6] Univ Western Ontario, London, ON, Canada

[7] CIBERehd, IDIBAPS, Hosp Clin, Dept Gastroenterol, Barcelona, Spain

[8] Ist Clin Humanitas, Dept Gastroenterol, Rozzano, Italy

[9] Univ Kiel, Univ Hosp Kiel, Kiel, Germany

[10] Keio Univ, Sch Med, Tokyo, Japan

[11] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA

[12] Univ Paris, Univ Paris 06, F-75252 Paris, France

[13] Univ Paris, Hop St Antoine, AP HP, Dept Gastroenterol, F-75252 Paris, France

[14] Dept Gastroenterol, Haifa, Israel

[15] Technion Israel Inst Technol, Bruce Rappaport Sch Med, Haifa, Israel

[16] Univ Liege, CHU Liege, Dept Gastroenterol, Liege, Belgium

[17] Univ Liege, GIGA Res, Liege, Belgium

[18] Hosp Israelita Albert Einstein, Sao Paulo, Brazil

[19] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria

[20] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[21] Univ Lille Nord France, CHU Lille, Lille, France

[22] John Radcliffe Hosp, Translat Gastroenterol Unit, Oxford OX3 9DU, England

[23] Univ Calif San Diego, La Jolla, CA 92093 USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2012年 / 107卷 / 12期

关键词：

EARLY MULTIPLE-SCLEROSIS; INTESTINAL FIBROSIS; BOWEL OBSTRUCTION; NATURAL-HISTORY; RISK-FACTORS; COMPLICATIONS; REMISSION; THERAPY; CLASSIFICATION; INFLAMMATION;

D O I：

10.1038/ajg.2012.117

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We report the findings and outputs of an international expert opinion process to develop a definition of early Crohn's disease (CD) that could be used in future disease-modification trials. Nineteen experts on inflammatory bowel diseases held an international expert opinion meeting to discuss and agree on a definition for early CD to be used in disease-modification trials. The process included literature searches for the relevant basic-science and clinical evidence. A published preliminary definition of early CD was used as the basis for development of a proposed definition that was discussed at the expert opinion meeting. The participants then derived a final definition, based on best current knowledge, that it is hoped will be of practical use in disease-modification trials in CD. Am J Gastroenterol 2012;107:1770-1776; doi:10.1038/ajg.2012.117

引用

页码：1770 / 1776

页数：7

共 50 条

[1] Early Crohn disease: a proposed definition for use in disease-modification trials
Peyrin-Biroulet, Laurent
Loftus, Edward V., Jr.
Colombel, Jean-Frederic
Sandborn, William J.
GUT, 2010, 59 (02) : 141 - 147
[2] Applications of neuroimaging to disease-modification trials in Alzheimer's disease
Fleisher, Adam S.
Donohue, Michael
Chen, Kewei
Brewer, James B.
Aisen, Paul S.
BEHAVIOURAL NEUROLOGY, 2009, 21 (1-2) : 129 - 136
[3] Mixed results for disease-modification strategies for Alzheimer's disease
Alisa Opar
Nature Reviews Drug Discovery, 2008, 7 : 717 - 718
[4] Prodromal Parkinson's disease: hype or hope for disease-modification trials?
Mahlknecht, Philipp
Marini, Kathrin
Werkmann, Mario
Poewe, Werner
Seppi, Klaus
TRANSLATIONAL NEURODEGENERATION, 2022, 11 (01)
[5] Early intervention in Crohn's disease: towards disease modification trials
Danese, Silvio
Fiorino, Gionata
Peyrin-Biroulet, Laurent
GUT, 2017, 66 (12) : 2179 - 2187
[6] Mixed results for disease-modification strategies for Alzheimer's disease
Opar, Alisa
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) : 717 - 718
[7] Prodromal Parkinson's disease: hype or hope for disease-modification trials?
Philipp Mahlknecht
Kathrin Marini
Mario Werkmann
Werner Poewe
Klaus Seppi
Translational Neurodegeneration, 11
[8] Ustekinumab in the management of Crohn's disease: Expert opinion
Armuzzi, Alessandro
Ardizzone, Sandro
Biancone, Livia
Castiglione, Fabiana
Danese, Silvio
Gionchetti, Paolo
Orlando, Ambrogio
Rizzello, Fernando
Scribano, Maria Lia
Vecchi, Maurizio
Daperno, Marco
DIGESTIVE AND LIVER DISEASE, 2018, 50 (07) : 653 - 660
[9] A review and expert opinion of the use of certolizumab for Crohn's disease
Evans, Ashley T.
Lee, Scott D.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (03) : 363 - 370
[10] ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease
D J Stone
C Molony
C Suver
E E Schadt
W Z Potter
The Pharmacogenomics Journal, 2010, 10 : 161 - 164

← 1 2 3 4 5 →